Development and Validation of an Immunotherapy-Related Prognostic Signature Based on Lymph Node Ratio for Gastric Cancer

Figure 10

Association of LNR-base signature with immunotherapy and chemotherapy responsiveness in GC. The vioplot of the difference of the (a) TIDE score, (b) dysfunction score, (c) exclusion score between high- and low-risk groups. The barplot of the percentages of (d) immunotherapy responder predicted by the TIDE algorithm, (e) microsatellite status, (f) TMB between high-and low-risk groups in GC patients, and (g) correlations between risk scores and chemotherapeutic drugs. .

(a)

(b)

(c)x`

(d)

(e)

(f)

(g)